Recent Updates
Recently added Catalysts
BTAI Negative Sentiment Score: 20/100

BioXcel Therapeutics, Inc: Please contact the Portnoy Law Firm to recover your losses; September 5, 2023 deadline.

Key Takeaway: BioXcel Therapeutics, Inc. (BTAI) is facing a class action lawsuit for allegedly making materially false statements regarding its business operations from December 15, 2021, to June 28, 2023. The lawsuit highlights serious internal control deficiencies and failures related to compliance with regulatory protocols. These issues potentially impacted the company's regulatory approval prospects for BXCL501, a treatment intended for agitation in dementia patients. Investors interested in recovering their losses are encouraged to contact the Portnoy Law Firm for legal assistance.

Market Sentiment Analysis

CONCERNS & RISKS

  • Lawsuit filed due to materially false and deceptive statements made by company executives.
  • Allegations of inadequate internal controls and failure to comply with established protocols.
  • Concerns over data integrity and issues impacting regulatory approval for BXCL501.

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, Aug. 21, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) investors that a lawsuit filed on behalf of investors that purchased BioXcel securities between December 15, 2021 and June 28, 2023, both dates inclusive (the “Class Period”).
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The lawsuit filed in this class action asserts that during the designated period, the Defendants made statements that were materially false and/or deceptive, and also neglected to disclose crucial negative information about the Company's business, operations, and future prospects. Specifically, the Defendants failed to inform investors of the following: (1) the Company's inadequate internal controls concerning adherence to protocols and data integrity; (2) the failure of the Company's principal investigator to comply with the approved informed consent form from the Institutional Review Board; (3) the inadequate maintenance of complete case histories for certain patients whose records were reviewed by the FDA; (4) the fabrication of email correspondence between the Company's principal investigator and a pharmacovigilance safety vendor, which was then submitted to the FDA; (5) the detrimental impact of these issues on the Company's ability to obtain regulatory approval for BXCL501 as a treatment for agitation associated with dementia in probable Alzheimer's disease patients; and (6) as a result of the aforementioned issues, the Defendants' positive statements about the Company's business, operations, and prospects were significantly misleading and lacked a reasonable basis.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Attorney Advertising

Tags

Frequently Asked Questions

How can BioXcel investors recover losses?

Investors can contact the Portnoy Law Firm for a free case evaluation.

What is the timeline of the BioXcel securities class period?

The class period for the lawsuit is from December 15, 2021, to June 28, 2023.

What allegations are made in the BioXcel lawsuit?

The lawsuit claims the company made false statements and hid critical information.

Who should investors contact for more information?

Investors can reach out to attorney Lesley F. Portnoy at 844-767-8529.

What kind of issues does the lawsuit address?

The lawsuit highlights issues related to internal controls and misrepresentation.

Last updated: Aug 21, 2023